Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM-Reference-Cited by-同舟云学术

Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM

Published:2010-05-13 Issue:10 Volume:17 Page:1234-1243
ISSN:0969-7128
Container-title:Gene Therapy
language:en
Short-container-title:Gene Ther

Author:

Xin C,Ye S,Ming Y,Shenghua Z,Qingfang M,Hongxing G,Xu S,Yuanfu X,Yuan Z,Dongmei F,Juanni L,Yingdai G,Lianfang J,Rongguang S,Zhenping Z,Jianxiang W,Tao C,Chunzheng Y,Dongsheng X,Yongsu Z

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/gt201076.pdf

Reference27 articles.

1. van de Loosdrecht AA, Huijgens PC, Ossenkoppele GJ . Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin's lymphoma. Curr Opin Hematol 2004; 11: 419–425.

2. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490–1496.

3. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.

4. Hu JL, Xue YC, Xie MY, Zhang R, Otani T, Minami Y et al. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo) 1988; 41: 1575–1579.

5. Otani T, Minami Y, Marunaka T, Zhang R, Xie MY . A new macromolecular antitumor antibiotic, C-1027. II. Isolation and physico-chemical properties. J Antibiot (Tokyo) 1988; 41: 1580–1585.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates;Antibody Therapeutics;2021-01-01

2. Induction of apoptosis and erythroid differentiation of human chronic myelogenous leukemia K562 cells by low concentrations of lidamycin;Oncology Reports;2018-11-02

3. A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues;BMC Cancer;2016-02-20

4. The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3;Cancer Biology & Therapy;2015-07-17

5. A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma;Basic & Clinical Pharmacology & Toxicology;2015-02-20